{"gene":"GNA12","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2006,"finding":"The GTPase-deficient activated mutant of Gα12 (gep oncogene) activates STAT3 via phosphorylation at Tyrosine-705 (through JAK3 and Src kinase) and Serine-727 (through PDGFRα and PI3K). Dominant-negative STAT3 inhibits foci formation and anchorage-independent growth of Gα12QL-transfectants, establishing STAT3 as a critical mediator of Gα12-driven neoplastic transformation.","method":"Constitutively active Gα12QL transfection, phospho-STAT3 immunoblotting, dominant-negative STAT3 co-expression, foci formation and soft-agar colony assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean loss-of-function/gain-of-function with defined cellular phenotype, two orthogonal functional readouts (foci + anchorage-independent growth), single lab","pmids":["16247467"],"is_preprint":false},{"year":2009,"finding":"Gα12 and Gα13 (gep oncogenes) upregulate TGFβ1 gene expression through a Rho/Rac-dependent increase in AP-1 (c-Jun) transcriptional activity. Knockdown or knockout of Gα12/Gα13 in murine embryonic fibroblasts and hepatic stellate cells reduced constitutive and thrombin-inducible TGFβ1 expression; activated mutants rescued expression in knockout cells. Dominant-negative Rho or Rac (but not Cdc42) prevented gene transactivation.","method":"siRNA knockdown, knockout MEFs, activated mutant transfection, promoter-deletion reporter assay, AP-1 activity assay, dominant-negative Rho/Rac/Cdc42 co-expression","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic approaches (KO, KD, activated mutant rescue), promoter dissection with AP-1 site mutation, dominant-negative epistasis, consistent across two cell types","pmids":["19151758"],"is_preprint":false},{"year":2011,"finding":"The scaffold protein JLP (JNK-interacting leucine zipper protein) physically associates with Gα12, and this interaction is enhanced by receptor- or mutation-mediated Gα12 activation. JLP binds Gα12 through its C-terminal domain. Disruption of the Gα12-JLP interaction (using C-terminal domain as competitive inhibitor) abrogates Gα12-stimulated JNK activation and prevents Gα12- and Gα13-mediated neoplastic transformation.","method":"Co-immunoprecipitation, competitive inhibition with C-terminal domain peptide, JNK activity assay, neoplastic transformation (foci formation) assay","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional disruption with defined phenotype (transformation), single lab, two orthogonal approaches","pmids":["21472140"],"is_preprint":false},{"year":2011,"finding":"LPA stimulates proliferation of ovarian cancer cells via Gα12 (the gep proto-oncogene). LPA activates Gα12 rapidly in SKOV-3 cells. An inhibitory minigene (CT12) disrupting LPAR-Gα12 interaction and shRNA silencing of Gα12 drastically attenuate LPA-mediated proliferation of SKOV3, Hey, and OVCAR-3 cells. Silencing Gα12 does not significantly affect LPA-mediated migration, indicating a proliferation-specific role.","method":"shRNA silencing, inhibitory minigene (CT12) expression, cell proliferation assay, migration assay, Gα12 activation assay","journal":"Genes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal inhibition approaches (shRNA + dominant-negative minigene), tested across multiple cell lines, single lab","pmids":["21901169"],"is_preprint":false},{"year":2013,"finding":"Gα12 (gep proto-oncogene) mediates LPA-stimulated activation of CREB in ovarian cancer cells through a cAMP-independent, Ras-ERK-dependent mechanism. LPA-stimulated CREB phosphorylation at Ser133 is detected within 3 minutes. Constitutively active Gα12 stimulates CREB even without LPA; silencing Gα12 attenuates LPA-stimulated CREB phosphorylation. Expression of dominant-negative CREB (S133A) reduces LPA-stimulated proliferation of HeyA8 cells.","method":"Protein/DNA array analysis, constitutively active Gα12 expression, Gα12 siRNA silencing, phospho-CREB immunoblotting, dominant-negative CREB (S133A) expression, proliferation assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (gain-of-function, loss-of-function, dominant-negative downstream), pathway dissection, single lab","pmids":["24055910"],"is_preprint":false},{"year":2014,"finding":"Gα12 overexpression in HCC causes ZEB1 induction by deregulating p53-responsive microRNA clusters (miR-200b/a/429, miR-194-2/192, miR-194-1/215) via AP-1/c-Jun-mediated MDM2 induction that reduces p53 levels. This promotes epithelial-mesenchymal transition. Sustained knockdown of Gα12 in SK-Hep1 cells (mesenchymal-type) decreased xenograft tumor growth rate and volume. Transfection with miR-200b, -192 or -215 mimic prevented Gα12QL-induced tumor cell migration/invasion.","method":"Activated Gα12QL transfection, miRNome profiling, cDNA microarray, miRNA mimic transfection, Gα12 shRNA knockdown, xenograft tumor model, integrative miRNA-mRNA network analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (miRNome, cDNA array, miRNA mimics, shRNA KD, xenograft), mechanistic pathway defined from Gα12 through AP-1/MDM2/p53 to miRNA to ZEB1","pmids":["25065598"],"is_preprint":false},{"year":2015,"finding":"Silencing of Gα12 and Gα13 (gep oncogenes) drastically attenuates serum- or LPA-stimulated proliferation of SKOV3 ovarian cancer cells. In xenograft models, silencing of Gα13 drastically reduced tumor growth and prolonged mouse survival; silencing of Gα12 had a similar but reduced effect. Silencing of Gαi2 or Gαq had no such effect, establishing Gα12/13 as the determinant α-subunits for ovarian cancer growth in vivo.","method":"siRNA silencing of individual Gα-subunits, proliferation assay, invasion/migration assay, xenograft tumor model with survival analysis","journal":"Genes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo xenograft with genetic silencing of specific G-protein subunits, epistatic comparison across multiple Gα subunits, single lab","pmids":["26413218"],"is_preprint":false},{"year":2016,"finding":"Gα12/13 (encoded by GNA12/GNA13; gep oncogene) promotes proliferation of ovarian cancer cells by activating the transcriptional coactivator YAP, a component of the Hippo signaling pathway. A synthetic biology approach using chimeric G proteins and designer GPCRs confirmed selective Gα12/13 signaling to YAP. YAP inhibition by shRNA or a specific inhibitor prevented ovarian cancer cell growth.","method":"Chimeric G protein/designer GPCR (DREADD) approach for selective pathway activation, YAP activity assays, shRNA knockdown, YAP-specific inhibitor treatment, cell growth assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — synthetic biology approach with selective G-protein pathway activation, loss-of-function with shRNA and pharmacological inhibitor, multiple orthogonal methods in single study","pmids":["26804165"],"is_preprint":false},{"year":2017,"finding":"c-Jun transcription factor binds to the GNA12 5' regulatory region and controls GNA12 transcription in prostate cancer cells. Deletion analysis identified a minimal 784 bp promoter region with c-Jun, C/EBP, and CREB1 binding sites. siRNA silencing of c-Jun reduced GNA12 reporter activity, mRNA, and protein levels in PC3 cells but did not reduce GNA13 levels, indicating specific regulation of GNA12.","method":"GNA12 promoter cloning, luciferase reporter assays with deletion analysis, siRNA knockdown of c-Jun, chromatin immunoprecipitation (ChIP), RT-qPCR and immunoblotting","journal":"Molecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirmation plus functional reporter assays and siRNA, single lab, two orthogonal methods confirming c-Jun as transcriptional regulator","pmids":["28394299"],"is_preprint":false},{"year":2008,"finding":"RGS22, a testis-specific regulator of G-protein signaling, physically interacts with GNA12 (and GNA13 and GNA11). GNA13 and RGS22 co-localize in the nucleus from the elongated spermatid stage onward. Defective GNA13 expression was found in macrocephalic and globozoospermic spermatozoa, suggesting a functional role for GNA12/13 and RGS22 in spermiogenesis.","method":"Co-immunoprecipitation (GNA12 interaction with RGS22), GFP-fusion protein tracking, indirect immunofluorescence, testis histology","journal":"Biology of reproduction","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP for the GNA12 interaction, subcellular localization data for GNA13 rather than GNA12, no direct functional manipulation of GNA12","pmids":["18703424"],"is_preprint":false},{"year":2015,"finding":"The GNA12 promoter is hypomethylated at specific CpG sites in placenta and peripheral blood of preeclampsia patients compared to normal pregnant women, and this hypomethylation is associated with elevated GNA12 mRNA expression in placenta, suggesting epigenetic regulation of GNA12 expression via promoter methylation.","method":"MassARRAY methylation analysis of GNA12 promoter CpG sites in placenta and blood DNA, RT-qPCR for GNA12 mRNA","journal":"Annals of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — correlative methylation-expression association without functional manipulation, single method per endpoint, no mechanistic intervention","pmids":["26767593"],"is_preprint":false},{"year":2021,"finding":"A plant microRNA isoform (miR171vr) targets the human GNA12 transcript. Treatment of HEK293 cells with synthetic miR171vr significantly decreased GNA12 mRNA and protein levels, and modulated downstream GNA12 signaling factors including mTOR.","method":"Bioinformatics prediction of miRNA-mRNA interaction, synthetic microRNA transfection into HEK293 cells, RT-qPCR and immunoblotting for GNA12 and downstream signaling components","journal":"Molecular biology reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, confirmatory experiment using synthetic miRNA without 3'UTR reporter or rescue, limited mechanistic follow-up","pmids":["33386590"],"is_preprint":false},{"year":2008,"finding":"Examination of the GNA12 gene in familial hyperaldosteronism type II (FH-II) patients linked to chromosome 7p22 found no causative mutations in GNA12, providing a negative result for GNA12 as the causal gene for FH-II in the families studied.","method":"DNA sequencing of GNA12 coding regions in affected and unaffected members of 7p22-linked FH-II families","journal":"Clinical and experimental pharmacology & physiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — negative finding from candidate gene sequencing in small family cohort; informationally relevant as negative result","pmids":["18307725"],"is_preprint":false}],"current_model":"GNA12 encodes Gα12, the α-subunit of the G12 family of heterotrimeric G proteins (the gep proto-oncogene), which is activated downstream of GPCRs (including LPA receptors) and signals through multiple effectors: it activates JNK via the scaffold protein JLP, stimulates STAT3 phosphorylation via JAK3/Src (Tyr705) and PDGFRα/PI3K (Ser727), activates CREB via a Ras-ERK-dependent mechanism, promotes YAP activity through the Hippo pathway, upregulates TGFβ1 transcription via Rho/Rac-dependent AP-1 activation, and in HCC drives EMT by suppressing p53 (through AP-1/MDM2) to derepress ZEB1 via miR-200/192/215 clusters; GNA12 transcription itself is positively controlled by c-Jun binding to a minimal 784 bp promoter element."},"narrative":{"mechanistic_narrative":"GNA12 encodes Gα12, the α-subunit of the G12 heterotrimeric G protein (the gep proto-oncogene), which couples GPCR activation — notably LPA receptors — to a transcriptional program driving cell proliferation and neoplastic transformation [PMID:21901169, PMID:26413218]. Upon activation, Gα12 engages multiple effector routes: it associates with the scaffold protein JLP through JLP's C-terminal domain to drive JNK activation, an interaction required for Gα12/Gα13-mediated transformation [PMID:21472140]; it phosphorylates and activates STAT3 at Tyr705 (via JAK3/Src) and Ser727 (via PDGFRα/PI3K), with STAT3 acting as a critical mediator of transformation [PMID:16247467]; and it stimulates CREB phosphorylation at Ser133 through a cAMP-independent, Ras-ERK-dependent route that supports LPA-driven proliferation [PMID:24055910]. Through Rho/Rac-dependent activation of AP-1 (c-Jun), Gα12 upregulates TGFβ1 transcription [PMID:19151758], and it activates the Hippo-pathway coactivator YAP to promote ovarian cancer cell growth [PMID:26804165]. In hepatocellular carcinoma, activated Gα12 drives epithelial-mesenchymal transition by inducing MDM2 through AP-1/c-Jun, lowering p53 and thereby derepressing ZEB1 via the p53-responsive miR-200/192/215 microRNA clusters [PMID:25065598]. GNA12 expression is itself positively controlled by c-Jun binding to a minimal 784 bp promoter region [PMID:28394299]. In vivo, silencing Gα12 (and Gα13) reduces xenograft tumor growth, establishing the G12 family α-subunits as determinants of tumor growth [PMID:26413218].","teleology":[{"year":2006,"claim":"Established that activated Gα12 transforms cells through STAT3, identifying a defined downstream effector for gep oncogene-driven transformation.","evidence":"Constitutively active Gα12QL transfection with phospho-STAT3 immunoblotting, dominant-negative STAT3 co-expression, foci and soft-agar assays","pmids":["16247467"],"confidence":"Medium","gaps":["Single lab; mechanism of how Gα12 engages JAK3/Src and PDGFRα not resolved","STAT3 transcriptional targets in this context not defined"]},{"year":2008,"claim":"Tested whether GNA12 physically interacts with regulators and contributes to germ cell biology, linking it to RGS22 in the testis.","evidence":"Co-immunoprecipitation of GNA12 with RGS22, GFP-fusion tracking, immunofluorescence and testis histology","pmids":["18703424"],"confidence":"Low","gaps":["Single Co-IP for the GNA12 interaction without reciprocal validation","Localization and phenotype data were for GNA13, not GNA12","No functional manipulation of GNA12"]},{"year":2008,"claim":"Excluded GNA12 as the causal gene for familial hyperaldosteronism type II in 7p22-linked families, a negative genetic result.","evidence":"DNA sequencing of GNA12 coding regions in FH-II family members","pmids":["18307725"],"confidence":"Low","gaps":["Small cohort; coding-region only","Does not address regulatory or non-coding variants"]},{"year":2009,"claim":"Defined how Gα12/13 reprograms transcription, showing Rho/Rac-AP-1-dependent upregulation of TGFβ1.","evidence":"siRNA knockdown, knockout MEFs, activated mutant rescue, promoter-deletion reporter, AP-1 assay, dominant-negative Rho/Rac/Cdc42","pmids":["19151758"],"confidence":"High","gaps":["Effector linking Gα12 to Rho/Rac not specified","Physiological consequence of TGFβ1 induction not tracked in vivo"]},{"year":2011,"claim":"Identified JLP as a Gα12-binding scaffold required for JNK activation and transformation, providing a physical effector link.","evidence":"Co-IP, competitive inhibition with JLP C-terminal domain peptide, JNK activity assay, foci formation assay","pmids":["21472140"],"confidence":"Medium","gaps":["Single lab; structural basis of the interaction not resolved","How JLP couples to the JNK module downstream not detailed"]},{"year":2011,"claim":"Demonstrated that LPA drives ovarian cancer proliferation specifically through Gα12, separating proliferative from migratory signaling.","evidence":"shRNA silencing, inhibitory CT12 minigene disrupting LPAR-Gα12, proliferation and migration assays across multiple cell lines","pmids":["21901169"],"confidence":"Medium","gaps":["Downstream proliferative effectors not defined here","Single lab"]},{"year":2013,"claim":"Showed Gα12 mediates LPA-stimulated CREB activation via a cAMP-independent Ras-ERK route supporting proliferation.","evidence":"Constitutively active Gα12, siRNA silencing, phospho-CREB (Ser133) immunoblotting, dominant-negative CREB(S133A), proliferation assay","pmids":["24055910"],"confidence":"Medium","gaps":["Link between Gα12 and Ras not mechanistically resolved","CREB target genes not identified"]},{"year":2014,"claim":"Connected Gα12 to EMT in HCC through an AP-1/MDM2/p53/miRNA axis derepressing ZEB1, defining a transcriptional EMT mechanism.","evidence":"Gα12QL transfection, miRNome and cDNA profiling, miRNA mimics, shRNA knockdown, xenograft tumor model","pmids":["25065598"],"confidence":"High","gaps":["Whether the same axis operates in non-HCC tumors not established","Proximal effector linking Gα12 to AP-1/MDM2 not fully mapped"]},{"year":2015,"claim":"Established Gα12/13 as the determinant α-subunits for ovarian tumor growth in vivo, distinguishing them from Gαi2/Gαq.","evidence":"siRNA silencing of individual Gα subunits, proliferation and invasion assays, xenograft model with survival analysis","pmids":["26413218"],"confidence":"Medium","gaps":["Gα13 effect was stronger than Gα12; relative contributions not dissected mechanistically","Single lab"]},{"year":2015,"claim":"Linked GNA12 promoter hypomethylation to elevated expression in preeclampsia, implicating epigenetic control of GNA12.","evidence":"MassARRAY CpG methylation analysis of placenta and blood DNA with RT-qPCR","pmids":["26767593"],"confidence":"Low","gaps":["Correlative association without functional manipulation","Causal direction between methylation and expression not tested"]},{"year":2016,"claim":"Showed Gα12/13 selectively activates the Hippo coactivator YAP to drive ovarian cancer growth, adding a transcriptional growth effector.","evidence":"Chimeric G protein/DREADD selective pathway activation, YAP assays, shRNA knockdown, YAP inhibitor, growth assay","pmids":["26804165"],"confidence":"High","gaps":["Upstream Hippo kinase steps engaged by Gα12 not delineated","Single study"]},{"year":2017,"claim":"Identified c-Jun as a specific transcriptional regulator of GNA12, revealing a feedforward loop with AP-1-dependent Gα12 signaling.","evidence":"Promoter cloning, luciferase deletion analysis, ChIP, c-Jun siRNA, RT-qPCR and immunoblotting in PC3 cells","pmids":["28394299"],"confidence":"Medium","gaps":["Roles of the co-identified C/EBP and CREB1 sites not functionally tested","Single cell-type/single lab"]},{"year":2021,"claim":"Tested post-transcriptional regulation of GNA12, showing a plant-derived miRNA can lower GNA12 and modulate downstream mTOR signaling.","evidence":"Bioinformatic prediction and synthetic miR171vr transfection in HEK293 with RT-qPCR/immunoblot","pmids":["33386590"],"confidence":"Low","gaps":["No 3'UTR reporter or rescue to confirm direct targeting","Physiological relevance of plant miRNA targeting unclear"]},{"year":null,"claim":"How the diverse Gα12 effector branches (JLP-JNK, STAT3, CREB, Rho/Rac-AP-1, YAP, p53-miRNA) are integrated and selected in a given cell context remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model of effector selection downstream of Gα12","Structural/biochemical basis for differential effector engagement undefined","Limited in vivo validation outside xenograft models"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,4,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5,7]}],"localization":[],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,4,7]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,5,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,6]}],"complexes":[],"partners":["JLP","RGS22"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q03113","full_name":"Guanine nucleotide-binding protein subunit alpha-12","aliases":[],"length_aa":381,"mass_kda":44.3,"function":"Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems (PubMed:12515866, PubMed:15240885, PubMed:15525651, PubMed:16705036, PubMed:16787920, PubMed:17565996, PubMed:22609986, PubMed:23762476, PubMed:27084452). Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF12/LARG) (PubMed:12515866, PubMed:15240885, PubMed:16202387). GNA12-dependent Rho signaling subsequently regulates transcription factor AP-1 (activating protein-1) (By similarity). GNA12-dependent Rho signaling also regulates protein phosphatese 2A activation causing dephosphorylation of its target proteins (PubMed:15525651, PubMed:17565996). Promotes tumor cell invasion and metastasis by activating RhoA/ROCK signaling pathway and up-regulating pro-inflammatory cytokine production (PubMed:16705036, PubMed:16787920, PubMed:23762476, PubMed:27084452). Inhibits CDH1-mediated cell adhesion in process independent from Rho activation (PubMed:11976333, PubMed:16787920). Together with NAPA promotes CDH5 localization to plasma membrane (PubMed:15980433). May play a role in the control of cell migration through the TOR signaling cascade (PubMed:22609986)","subcellular_location":"Cell membrane; Lateral cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q03113/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNA12","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"EMC7","stoichiometry":0.2},{"gene":"GNB1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GNA12","total_profiled":1310},"omim":[{"mim_id":"615650","title":"REGULATOR OF G PROTEIN SIGNALING 22; RGS22","url":"https://www.omim.org/entry/615650"},{"mim_id":"609736","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 88A; CCDC88A","url":"https://www.omim.org/entry/609736"},{"mim_id":"608414","title":"PHOSPHOLIPASE C, EPSILON-1; PLCE1","url":"https://www.omim.org/entry/608414"},{"mim_id":"607894","title":"POLYCYSTIN 1-LIKE 2; PKD1L2","url":"https://www.omim.org/entry/607894"},{"mim_id":"607190","title":"REGULATOR OF G PROTEIN SIGNALING 13; RGS13","url":"https://www.omim.org/entry/607190"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GNA12"},"hgnc":{"alias_symbol":["gep"],"prev_symbol":[]},"alphafold":{"accession":"Q03113","domains":[{"cath_id":"3.40.50.300","chopping":"59-83_208-372","consensus_level":"medium","plddt":94.7213,"start":59,"end":372},{"cath_id":"1.10.400.10","chopping":"86-202","consensus_level":"medium","plddt":95.7857,"start":86,"end":202}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03113","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q03113-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q03113-F1-predicted_aligned_error_v6.png","plddt_mean":89.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNA12","jax_strain_url":"https://www.jax.org/strain/search?query=GNA12"},"sequence":{"accession":"Q03113","fasta_url":"https://rest.uniprot.org/uniprotkb/Q03113.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q03113/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03113"}},"corpus_meta":[{"pmid":"12634971","id":"PMC_12634971","title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.","date":"2003","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/12634971","citation_count":325,"is_preprint":false},{"pmid":"23091441","id":"PMC_23091441","title":"Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.","date":"2012","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/23091441","citation_count":190,"is_preprint":false},{"pmid":"17307734","id":"PMC_17307734","title":"Cartilage oligomeric matrix protein associates with granulin-epithelin precursor (GEP) and potentiates GEP-stimulated chondrocyte proliferation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17307734","citation_count":117,"is_preprint":false},{"pmid":"26958083","id":"PMC_26958083","title":"The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.","date":"2016","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26958083","citation_count":108,"is_preprint":false},{"pmid":"10940694","id":"PMC_10940694","title":"Interferon in the management of neuroendocrine GEP-tumors: a review.","date":"2000","source":"Digestion","url":"https://pubmed.ncbi.nlm.nih.gov/10940694","citation_count":105,"is_preprint":false},{"pmid":"11226253","id":"PMC_11226253","title":"ARF-GEP(100), a guanine nucleotide-exchange protein for ADP-ribosylation factor 6.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11226253","citation_count":97,"is_preprint":false},{"pmid":"19487464","id":"PMC_19487464","title":"ADAMTS-7, a direct target of PTHrP, adversely regulates endochondral bone growth by associating with and inactivating GEP growth factor.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19487464","citation_count":95,"is_preprint":false},{"pmid":"28837143","id":"PMC_28837143","title":"Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28837143","citation_count":93,"is_preprint":false},{"pmid":"10548487","id":"PMC_10548487","title":"nRap GEP: a novel neural GDP/GTP exchange protein for rap1 small G protein that interacts with synaptic scaffolding molecule (S-SCAM).","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10548487","citation_count":91,"is_preprint":false},{"pmid":"32883742","id":"PMC_32883742","title":"Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32883742","citation_count":85,"is_preprint":false},{"pmid":"6370932","id":"PMC_6370932","title":"Immunocytochemical investigation of the gastro-entero-pancreatic (GEP) neurohormonal peptides in the pancreas and gastrointestinal tract of the dogfish Squalus acanthias.","date":"1984","source":"Histochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6370932","citation_count":85,"is_preprint":false},{"pmid":"2807986","id":"PMC_2807986","title":"Chromogranin A (CgA) in the gastro-entero-pancreatic (GEP) endocrine system. II. CgA in mammalian entero-endocrine cells.","date":"1989","source":"Histochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2807986","citation_count":79,"is_preprint":false},{"pmid":"26971843","id":"PMC_26971843","title":"Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.","date":"2016","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26971843","citation_count":75,"is_preprint":false},{"pmid":"19082839","id":"PMC_19082839","title":"A GEP-ISFG collaborative study on the optimization of an X-STR decaplex: data on 15 Iberian and Latin American populations.","date":"2008","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19082839","citation_count":73,"is_preprint":false},{"pmid":"23582925","id":"PMC_23582925","title":"Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.","date":"2012","source":"Best practice & research. Clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23582925","citation_count":63,"is_preprint":false},{"pmid":"16044162","id":"PMC_16044162","title":"Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16044162","citation_count":61,"is_preprint":false},{"pmid":"31337043","id":"PMC_31337043","title":"Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31337043","citation_count":61,"is_preprint":false},{"pmid":"29387927","id":"PMC_29387927","title":"Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.","date":"2018","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/29387927","citation_count":61,"is_preprint":false},{"pmid":"22819619","id":"PMC_22819619","title":"Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.","date":"2012","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22819619","citation_count":57,"is_preprint":false},{"pmid":"17684767","id":"PMC_17684767","title":"Peptide receptor expression in GEP-NET.","date":"2007","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17684767","citation_count":54,"is_preprint":false},{"pmid":"31134150","id":"PMC_31134150","title":"PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31134150","citation_count":53,"is_preprint":false},{"pmid":"30009041","id":"PMC_30009041","title":"Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).","date":"2018","source":"Clinical diabetes and endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30009041","citation_count":51,"is_preprint":false},{"pmid":"26112388","id":"PMC_26112388","title":"Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.","date":"2015","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/26112388","citation_count":48,"is_preprint":false},{"pmid":"24905065","id":"PMC_24905065","title":"Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24905065","citation_count":47,"is_preprint":false},{"pmid":"2873113","id":"PMC_2873113","title":"Immunocytochemical identification and localization of peptide hormones in the gastro-entero-pancreatic (GEP) endocrine system of the mouse and a stomachless fish, Barbus conchonius.","date":"1986","source":"Histochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2873113","citation_count":46,"is_preprint":false},{"pmid":"2510808","id":"PMC_2510808","title":"Chromogranins in mammalian GEP endocrine cells: their distribution and interrelations with co-stored amines and peptides.","date":"1989","source":"Archives of histology and cytology","url":"https://pubmed.ncbi.nlm.nih.gov/2510808","citation_count":45,"is_preprint":false},{"pmid":"25065598","id":"PMC_25065598","title":"Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25065598","citation_count":44,"is_preprint":false},{"pmid":"29256148","id":"PMC_29256148","title":"Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?","date":"2017","source":"Reviews in endocrine & metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/29256148","citation_count":42,"is_preprint":false},{"pmid":"33831756","id":"PMC_33831756","title":"Predictive modeling of swell-strength of expansive soils using artificial intelligence approaches: ANN, ANFIS and GEP.","date":"2021","source":"Journal of environmental management","url":"https://pubmed.ncbi.nlm.nih.gov/33831756","citation_count":42,"is_preprint":false},{"pmid":"34947124","id":"PMC_34947124","title":"Predictive Modeling of Mechanical Properties of Silica Fume-Based Green Concrete Using Artificial Intelligence Approaches: MLPNN, ANFIS, and GEP.","date":"2021","source":"Materials (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34947124","citation_count":41,"is_preprint":false},{"pmid":"11852196","id":"PMC_11852196","title":"Results of the 1999-2000 collaborative exercise and proficiency testing program on mitochondrial DNA of the GEP-ISFG: an inter-laboratory study of the observed variability in the heteroplasmy level of hair from the same donor.","date":"2002","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/11852196","citation_count":39,"is_preprint":false},{"pmid":"33304317","id":"PMC_33304317","title":"mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33304317","citation_count":38,"is_preprint":false},{"pmid":"21901169","id":"PMC_21901169","title":"Lysophosphatidic Acid Stimulates the Proliferation of Ovarian Cancer Cells via the gep Proto-Oncogene Gα(12).","date":"2011","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21901169","citation_count":36,"is_preprint":false},{"pmid":"17261172","id":"PMC_17261172","title":"Inhibition of PC cell-derived growth factor (PCDGF)/granulin-epithelin precursor (GEP) decreased cell proliferation and invasion through downregulation of cyclin D and CDK4 and inactivation of MMP-2.","date":"2007","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17261172","citation_count":34,"is_preprint":false},{"pmid":"10924847","id":"PMC_10924847","title":"The 1998-1999 collaborative exercises and proficiency testing program on DNA typing of the Spanish and Portuguese Working Group of the International Society for Forensic Genetics (GEP-ISFG).","date":"2000","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/10924847","citation_count":34,"is_preprint":false},{"pmid":"26804165","id":"PMC_26804165","title":"GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26804165","citation_count":33,"is_preprint":false},{"pmid":"33386590","id":"PMC_33386590","title":"Plant miR171 modulates mTOR pathway in HEK293 cells by targeting GNA12.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33386590","citation_count":32,"is_preprint":false},{"pmid":"33914348","id":"PMC_33914348","title":"Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.","date":"2021","source":"International journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33914348","citation_count":32,"is_preprint":false},{"pmid":"15100502","id":"PMC_15100502","title":"Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.","date":"2004","source":"Nuclear medicine communications","url":"https://pubmed.ncbi.nlm.nih.gov/15100502","citation_count":32,"is_preprint":false},{"pmid":"25430657","id":"PMC_25430657","title":"GEP-NETs update: Biotherapy for neuroendocrine tumours.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25430657","citation_count":31,"is_preprint":false},{"pmid":"9825477","id":"PMC_9825477","title":"Biochemical diagnosis of neuroendocrine GEP tumor.","date":"1997","source":"The Yale journal of biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9825477","citation_count":30,"is_preprint":false},{"pmid":"21107762","id":"PMC_21107762","title":"Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.","date":"2010","source":"Annals of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21107762","citation_count":30,"is_preprint":false},{"pmid":"24693229","id":"PMC_24693229","title":"PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.","date":"2014","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/24693229","citation_count":30,"is_preprint":false},{"pmid":"24116352","id":"PMC_24116352","title":"Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.","date":"2013","source":"American journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/24116352","citation_count":30,"is_preprint":false},{"pmid":"31065847","id":"PMC_31065847","title":"Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.","date":"2019","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/31065847","citation_count":29,"is_preprint":false},{"pmid":"12842357","id":"PMC_12842357","title":"The 2000-2001 GEP-ISFG Collaborative Exercise on mtDNA: assessing the cause of unsuccessful mtDNA PCR amplification of hair shaft samples.","date":"2003","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/12842357","citation_count":29,"is_preprint":false},{"pmid":"18307725","id":"PMC_18307725","title":"Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II.","date":"2008","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18307725","citation_count":27,"is_preprint":false},{"pmid":"23508014","id":"PMC_23508014","title":"The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells.","date":"2013","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/23508014","citation_count":25,"is_preprint":false},{"pmid":"17950274","id":"PMC_17950274","title":"IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs).","date":"2007","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17950274","citation_count":25,"is_preprint":false},{"pmid":"18703424","id":"PMC_18703424","title":"RGS22, a novel testis-specific regulator of G-protein signaling involved in human and mouse spermiogenesis along with GNA12/13 subunits.","date":"2008","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18703424","citation_count":24,"is_preprint":false},{"pmid":"25183048","id":"PMC_25183048","title":"SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.","date":"2014","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/25183048","citation_count":24,"is_preprint":false},{"pmid":"11834294","id":"PMC_11834294","title":"Localization of mRNAs for subfamily of guanine nucleotide-exchange proteins (GEP) for ARFs (ADP-ribosylation factors) in the brain of developing and mature rats under normal and postaxotomy conditions.","date":"2002","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11834294","citation_count":24,"is_preprint":false},{"pmid":"19151758","id":"PMC_19151758","title":"The gep oncogenes, Galpha(12) and Galpha(13), upregulate the transforming growth factor-beta1 gene.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19151758","citation_count":23,"is_preprint":false},{"pmid":"16247467","id":"PMC_16247467","title":"Neoplastic transformation by the gep oncogene, Galpha12, involves signaling by STAT3.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16247467","citation_count":23,"is_preprint":false},{"pmid":"26805636","id":"PMC_26805636","title":"High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26805636","citation_count":23,"is_preprint":false},{"pmid":"30796708","id":"PMC_30796708","title":"The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.","date":"2019","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/30796708","citation_count":22,"is_preprint":false},{"pmid":"28218348","id":"PMC_28218348","title":"Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.","date":"2017","source":"Nuclear medicine review. Central & Eastern Europe","url":"https://pubmed.ncbi.nlm.nih.gov/28218348","citation_count":21,"is_preprint":false},{"pmid":"24636354","id":"PMC_24636354","title":"XBP1S, a BMP2-inducible transcription factor, accelerates endochondral bone growth by activating GEP growth factor.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24636354","citation_count":21,"is_preprint":false},{"pmid":"36535024","id":"PMC_36535024","title":"Toluene Tolerated Li9.88GeP1.96Sb0.04S11.88Cl0.12 Solid Electrolyte toward Ultrathin Membranes for All-Solid-State Lithium Batteries.","date":"2022","source":"Nano letters","url":"https://pubmed.ncbi.nlm.nih.gov/36535024","citation_count":21,"is_preprint":false},{"pmid":"16899347","id":"PMC_16899347","title":"Analysis of body fluid mixtures by mtDNA sequencing: An inter-laboratory study of the GEP-ISFG working group.","date":"2006","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/16899347","citation_count":21,"is_preprint":false},{"pmid":"35410228","id":"PMC_35410228","title":"Predictive modeling of Persian walnut (Juglans regia L.) in vitro proliferation media using machine learning approaches: a comparative study of ANN, KNN and GEP models.","date":"2022","source":"Plant methods","url":"https://pubmed.ncbi.nlm.nih.gov/35410228","citation_count":18,"is_preprint":false},{"pmid":"34648706","id":"PMC_34648706","title":"In Situ Formed Li-Ag Alloy Interface Enables Li10GeP2S12-Based All-Solid-State Lithium Batteries.","date":"2021","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/34648706","citation_count":18,"is_preprint":false},{"pmid":"16243467","id":"PMC_16243467","title":"Results of the 2003-2004 GEP-ISFG collaborative study on mitochondrial DNA: focus on the mtDNA profile of a mixed semen-saliva stain.","date":"2005","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/16243467","citation_count":18,"is_preprint":false},{"pmid":"6108001","id":"PMC_6108001","title":"Endocrine GEP-cells in primary testicular teratoma.","date":"1980","source":"Virchows Archiv. A, Pathological anatomy and histology","url":"https://pubmed.ncbi.nlm.nih.gov/6108001","citation_count":17,"is_preprint":false},{"pmid":"28394299","id":"PMC_28394299","title":"c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells.","date":"2017","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28394299","citation_count":16,"is_preprint":false},{"pmid":"24723670","id":"PMC_24723670","title":"GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).","date":"2014","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24723670","citation_count":16,"is_preprint":false},{"pmid":"37003347","id":"PMC_37003347","title":"Tissue-specific collagen hydroxylation at GEP/GDP triplets mediated by P4HA2.","date":"2023","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37003347","citation_count":16,"is_preprint":false},{"pmid":"16685387","id":"PMC_16685387","title":"GEP associates with wild-type p53 in hepatocellular carcinoma.","date":"2006","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/16685387","citation_count":16,"is_preprint":false},{"pmid":"19083807","id":"PMC_19083807","title":"2006 GEP-ISFG collaborative exercise on mtDNA: reflections about interpretation, artefacts, and DNA mixtures.","date":"2007","source":"Forensic science international. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19083807","citation_count":16,"is_preprint":false},{"pmid":"28429092","id":"PMC_28429092","title":"Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.","date":"2017","source":"World journal of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/28429092","citation_count":16,"is_preprint":false},{"pmid":"27326246","id":"PMC_27326246","title":"Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era.","date":"2016","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27326246","citation_count":16,"is_preprint":false},{"pmid":"24055910","id":"PMC_24055910","title":"The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24055910","citation_count":15,"is_preprint":false},{"pmid":"26413218","id":"PMC_26413218","title":"Determinant role for the gep oncogenes, Gα12/13, in ovarian cancer cell proliferation and xenograft tumor growth.","date":"2015","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26413218","citation_count":15,"is_preprint":false},{"pmid":"35158852","id":"PMC_35158852","title":"Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35158852","citation_count":14,"is_preprint":false},{"pmid":"39235614","id":"PMC_39235614","title":"The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE.","date":"2024","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/39235614","citation_count":14,"is_preprint":false},{"pmid":"19948334","id":"PMC_19948334","title":"Forensic analysis of dog (Canis lupus familiaris) mitochondrial DNA sequences: an inter-laboratory study of the GEP-ISFG working group.","date":"2009","source":"Forensic science international. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19948334","citation_count":13,"is_preprint":false},{"pmid":"26767593","id":"PMC_26767593","title":"Preeclampsia is Associated with Decreased Methylation of the GNA12 Promoter.","date":"2015","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26767593","citation_count":12,"is_preprint":false},{"pmid":"21472140","id":"PMC_21472140","title":"Neoplastic transformation induced by the gep oncogenes involves the scaffold protein JNK-interacting leucine zipper protein.","date":"2011","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21472140","citation_count":12,"is_preprint":false},{"pmid":"34482177","id":"PMC_34482177","title":"Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).","date":"2021","source":"European journal of radiology","url":"https://pubmed.ncbi.nlm.nih.gov/34482177","citation_count":12,"is_preprint":false},{"pmid":"22179841","id":"PMC_22179841","title":"GEP constitutes a negative feedback loop with MyoD and acts as a novel mediator in controlling skeletal muscle differentiation.","date":"2011","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22179841","citation_count":12,"is_preprint":false},{"pmid":"34950969","id":"PMC_34950969","title":"[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective.","date":"2021","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/34950969","citation_count":11,"is_preprint":false},{"pmid":"1702388","id":"PMC_1702388","title":"Therapeutic strategies in the management of endocrine GEP tumours.","date":"1990","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/1702388","citation_count":11,"is_preprint":false},{"pmid":"34471940","id":"PMC_34471940","title":"Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/34471940","citation_count":10,"is_preprint":false},{"pmid":"36152904","id":"PMC_36152904","title":"Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations.","date":"2022","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36152904","citation_count":10,"is_preprint":false},{"pmid":"24375390","id":"PMC_24375390","title":"Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?","date":"2014","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24375390","citation_count":10,"is_preprint":false},{"pmid":"30518724","id":"PMC_30518724","title":"Metabolic Discrimination of Different Rhodiola Species Using 1H-NMR and GEP Combinational Chemometrics.","date":"2018","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/30518724","citation_count":10,"is_preprint":false},{"pmid":"32405630","id":"PMC_32405630","title":"Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.","date":"2020","source":"Cancer medicine journal","url":"https://pubmed.ncbi.nlm.nih.gov/32405630","citation_count":10,"is_preprint":false},{"pmid":"36197083","id":"PMC_36197083","title":"Effect of Solvents on a Li10GeP2S12-Based Composite Electrolyte via Solution Method for Solid-State Battery Applications.","date":"2022","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/36197083","citation_count":10,"is_preprint":false},{"pmid":"12927417","id":"PMC_12927417","title":"Results of the GEP-ISFG collaborative study on the Y chromosome STRs GATA A10, GATA C4, GATA H4, DYS437, DYS438, DYS439, DYS460 and DYS461: population data.","date":"2003","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/12927417","citation_count":10,"is_preprint":false},{"pmid":"32384260","id":"PMC_32384260","title":"c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.","date":"2020","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32384260","citation_count":9,"is_preprint":false},{"pmid":"40274320","id":"PMC_40274320","title":"Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.","date":"2025","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/40274320","citation_count":9,"is_preprint":false},{"pmid":"36925732","id":"PMC_36925732","title":"Comparative Metastatic Rates in GEP Class 1A versus 1B Posterior Uveal Melanoma: Results Contrary to Expectations.","date":"2022","source":"Ocular oncology and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36925732","citation_count":9,"is_preprint":false},{"pmid":"225792","id":"PMC_225792","title":"Majority and minority cell populations in GEP and bronchial endocrine tumours.","date":"1979","source":"Scandinavian journal of gastroenterology. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/225792","citation_count":9,"is_preprint":false},{"pmid":"36672462","id":"PMC_36672462","title":"Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672462","citation_count":8,"is_preprint":false},{"pmid":"37958406","id":"PMC_37958406","title":"Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy-A Systematic Review.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37958406","citation_count":8,"is_preprint":false},{"pmid":"26817437","id":"PMC_26817437","title":"GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.","date":"2016","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26817437","citation_count":8,"is_preprint":false},{"pmid":"21821488","id":"PMC_21821488","title":"SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS).","date":"2011","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/21821488","citation_count":8,"is_preprint":false},{"pmid":"29785545","id":"PMC_29785545","title":"Development of GP and GEP models to estimate an environmental issue induced by blasting operation.","date":"2018","source":"Environmental monitoring and assessment","url":"https://pubmed.ncbi.nlm.nih.gov/29785545","citation_count":8,"is_preprint":false},{"pmid":"35631902","id":"PMC_35631902","title":"GEP Tree-Based Prediction Model for Interfacial Bond Strength of Externally Bonded FRP Laminates on Grooves with Concrete Prism.","date":"2022","source":"Polymers","url":"https://pubmed.ncbi.nlm.nih.gov/35631902","citation_count":8,"is_preprint":false},{"pmid":"33354174","id":"PMC_33354174","title":"Clinical efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A \"not-so-promising\" result compared to GEP-NETs.","date":"2020","source":"World journal of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33354174","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55573,"output_tokens":4394,"usd":0.116315,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11679,"output_tokens":3825,"usd":0.07701,"stage2_stop_reason":"end_turn"},"total_usd":0.193325,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking through the abstracts, I need to identify papers about GNA12 (the G protein alpha 12 subunit, also known as the gep proto-oncogene). Many papers in this corpus are about \"GEP\" as an acronym for gastroenteropancreatic neuroendocrine tumors, forensic genetics working groups, gene expression programming, or granulin-epithelin precursor (a completely different protein). I need to carefully filter for papers specifically about GNA12/Gα12.\n\nRelevant papers about GNA12:\n- PMID:25065598 (Gα12 in HCC, EMT, miRNA)\n- PMID:21901169 (LPA-Gα12 in ovarian cancer proliferation)\n- PMID:23508014 (Gα13 in pancreatic cancer - this is GNA13, not GNA12, but mentions both)\n- PMID:26804165 (GEP oncogene/Gα12/13 and YAP in ovarian cancer)\n- PMID:19151758 (Gα12/13 upregulate TGFβ1)\n- PMID:16247467 (Gα12 and STAT3)\n- PMID:21472140 (Gα12/13 and JLP scaffold)\n- PMID:28394299 (c-Jun controls GNA12 transcription)\n- PMID:18703424 (RGS22 interacts with GNA12/13 in spermiogenesis)\n- PMID:26767593 (GNA12 promoter methylation in preeclampsia)\n- PMID:33386590 (plant miR171 targets GNA12)\n- PMID:24055910 (Gα12 mediates LPA→CREB in ovarian cancer)\n- PMID:26413218 (Gα12/13 in ovarian cancer xenograft)\n- PMID:18307725 (GNA12 examined in familial hyperaldosteronism - no mutations found)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"The GTPase-deficient activated mutant of Gα12 (gep oncogene) activates STAT3 via phosphorylation at Tyrosine-705 (through JAK3 and Src kinase) and Serine-727 (through PDGFRα and PI3K). Dominant-negative STAT3 inhibits foci formation and anchorage-independent growth of Gα12QL-transfectants, establishing STAT3 as a critical mediator of Gα12-driven neoplastic transformation.\",\n      \"method\": \"Constitutively active Gα12QL transfection, phospho-STAT3 immunoblotting, dominant-negative STAT3 co-expression, foci formation and soft-agar colony assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean loss-of-function/gain-of-function with defined cellular phenotype, two orthogonal functional readouts (foci + anchorage-independent growth), single lab\",\n      \"pmids\": [\"16247467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Gα12 and Gα13 (gep oncogenes) upregulate TGFβ1 gene expression through a Rho/Rac-dependent increase in AP-1 (c-Jun) transcriptional activity. Knockdown or knockout of Gα12/Gα13 in murine embryonic fibroblasts and hepatic stellate cells reduced constitutive and thrombin-inducible TGFβ1 expression; activated mutants rescued expression in knockout cells. Dominant-negative Rho or Rac (but not Cdc42) prevented gene transactivation.\",\n      \"method\": \"siRNA knockdown, knockout MEFs, activated mutant transfection, promoter-deletion reporter assay, AP-1 activity assay, dominant-negative Rho/Rac/Cdc42 co-expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic approaches (KO, KD, activated mutant rescue), promoter dissection with AP-1 site mutation, dominant-negative epistasis, consistent across two cell types\",\n      \"pmids\": [\"19151758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The scaffold protein JLP (JNK-interacting leucine zipper protein) physically associates with Gα12, and this interaction is enhanced by receptor- or mutation-mediated Gα12 activation. JLP binds Gα12 through its C-terminal domain. Disruption of the Gα12-JLP interaction (using C-terminal domain as competitive inhibitor) abrogates Gα12-stimulated JNK activation and prevents Gα12- and Gα13-mediated neoplastic transformation.\",\n      \"method\": \"Co-immunoprecipitation, competitive inhibition with C-terminal domain peptide, JNK activity assay, neoplastic transformation (foci formation) assay\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional disruption with defined phenotype (transformation), single lab, two orthogonal approaches\",\n      \"pmids\": [\"21472140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LPA stimulates proliferation of ovarian cancer cells via Gα12 (the gep proto-oncogene). LPA activates Gα12 rapidly in SKOV-3 cells. An inhibitory minigene (CT12) disrupting LPAR-Gα12 interaction and shRNA silencing of Gα12 drastically attenuate LPA-mediated proliferation of SKOV3, Hey, and OVCAR-3 cells. Silencing Gα12 does not significantly affect LPA-mediated migration, indicating a proliferation-specific role.\",\n      \"method\": \"shRNA silencing, inhibitory minigene (CT12) expression, cell proliferation assay, migration assay, Gα12 activation assay\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal inhibition approaches (shRNA + dominant-negative minigene), tested across multiple cell lines, single lab\",\n      \"pmids\": [\"21901169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Gα12 (gep proto-oncogene) mediates LPA-stimulated activation of CREB in ovarian cancer cells through a cAMP-independent, Ras-ERK-dependent mechanism. LPA-stimulated CREB phosphorylation at Ser133 is detected within 3 minutes. Constitutively active Gα12 stimulates CREB even without LPA; silencing Gα12 attenuates LPA-stimulated CREB phosphorylation. Expression of dominant-negative CREB (S133A) reduces LPA-stimulated proliferation of HeyA8 cells.\",\n      \"method\": \"Protein/DNA array analysis, constitutively active Gα12 expression, Gα12 siRNA silencing, phospho-CREB immunoblotting, dominant-negative CREB (S133A) expression, proliferation assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (gain-of-function, loss-of-function, dominant-negative downstream), pathway dissection, single lab\",\n      \"pmids\": [\"24055910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Gα12 overexpression in HCC causes ZEB1 induction by deregulating p53-responsive microRNA clusters (miR-200b/a/429, miR-194-2/192, miR-194-1/215) via AP-1/c-Jun-mediated MDM2 induction that reduces p53 levels. This promotes epithelial-mesenchymal transition. Sustained knockdown of Gα12 in SK-Hep1 cells (mesenchymal-type) decreased xenograft tumor growth rate and volume. Transfection with miR-200b, -192 or -215 mimic prevented Gα12QL-induced tumor cell migration/invasion.\",\n      \"method\": \"Activated Gα12QL transfection, miRNome profiling, cDNA microarray, miRNA mimic transfection, Gα12 shRNA knockdown, xenograft tumor model, integrative miRNA-mRNA network analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (miRNome, cDNA array, miRNA mimics, shRNA KD, xenograft), mechanistic pathway defined from Gα12 through AP-1/MDM2/p53 to miRNA to ZEB1\",\n      \"pmids\": [\"25065598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Silencing of Gα12 and Gα13 (gep oncogenes) drastically attenuates serum- or LPA-stimulated proliferation of SKOV3 ovarian cancer cells. In xenograft models, silencing of Gα13 drastically reduced tumor growth and prolonged mouse survival; silencing of Gα12 had a similar but reduced effect. Silencing of Gαi2 or Gαq had no such effect, establishing Gα12/13 as the determinant α-subunits for ovarian cancer growth in vivo.\",\n      \"method\": \"siRNA silencing of individual Gα-subunits, proliferation assay, invasion/migration assay, xenograft tumor model with survival analysis\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo xenograft with genetic silencing of specific G-protein subunits, epistatic comparison across multiple Gα subunits, single lab\",\n      \"pmids\": [\"26413218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Gα12/13 (encoded by GNA12/GNA13; gep oncogene) promotes proliferation of ovarian cancer cells by activating the transcriptional coactivator YAP, a component of the Hippo signaling pathway. A synthetic biology approach using chimeric G proteins and designer GPCRs confirmed selective Gα12/13 signaling to YAP. YAP inhibition by shRNA or a specific inhibitor prevented ovarian cancer cell growth.\",\n      \"method\": \"Chimeric G protein/designer GPCR (DREADD) approach for selective pathway activation, YAP activity assays, shRNA knockdown, YAP-specific inhibitor treatment, cell growth assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — synthetic biology approach with selective G-protein pathway activation, loss-of-function with shRNA and pharmacological inhibitor, multiple orthogonal methods in single study\",\n      \"pmids\": [\"26804165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"c-Jun transcription factor binds to the GNA12 5' regulatory region and controls GNA12 transcription in prostate cancer cells. Deletion analysis identified a minimal 784 bp promoter region with c-Jun, C/EBP, and CREB1 binding sites. siRNA silencing of c-Jun reduced GNA12 reporter activity, mRNA, and protein levels in PC3 cells but did not reduce GNA13 levels, indicating specific regulation of GNA12.\",\n      \"method\": \"GNA12 promoter cloning, luciferase reporter assays with deletion analysis, siRNA knockdown of c-Jun, chromatin immunoprecipitation (ChIP), RT-qPCR and immunoblotting\",\n      \"journal\": \"Molecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirmation plus functional reporter assays and siRNA, single lab, two orthogonal methods confirming c-Jun as transcriptional regulator\",\n      \"pmids\": [\"28394299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RGS22, a testis-specific regulator of G-protein signaling, physically interacts with GNA12 (and GNA13 and GNA11). GNA13 and RGS22 co-localize in the nucleus from the elongated spermatid stage onward. Defective GNA13 expression was found in macrocephalic and globozoospermic spermatozoa, suggesting a functional role for GNA12/13 and RGS22 in spermiogenesis.\",\n      \"method\": \"Co-immunoprecipitation (GNA12 interaction with RGS22), GFP-fusion protein tracking, indirect immunofluorescence, testis histology\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP for the GNA12 interaction, subcellular localization data for GNA13 rather than GNA12, no direct functional manipulation of GNA12\",\n      \"pmids\": [\"18703424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The GNA12 promoter is hypomethylated at specific CpG sites in placenta and peripheral blood of preeclampsia patients compared to normal pregnant women, and this hypomethylation is associated with elevated GNA12 mRNA expression in placenta, suggesting epigenetic regulation of GNA12 expression via promoter methylation.\",\n      \"method\": \"MassARRAY methylation analysis of GNA12 promoter CpG sites in placenta and blood DNA, RT-qPCR for GNA12 mRNA\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — correlative methylation-expression association without functional manipulation, single method per endpoint, no mechanistic intervention\",\n      \"pmids\": [\"26767593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A plant microRNA isoform (miR171vr) targets the human GNA12 transcript. Treatment of HEK293 cells with synthetic miR171vr significantly decreased GNA12 mRNA and protein levels, and modulated downstream GNA12 signaling factors including mTOR.\",\n      \"method\": \"Bioinformatics prediction of miRNA-mRNA interaction, synthetic microRNA transfection into HEK293 cells, RT-qPCR and immunoblotting for GNA12 and downstream signaling components\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, confirmatory experiment using synthetic miRNA without 3'UTR reporter or rescue, limited mechanistic follow-up\",\n      \"pmids\": [\"33386590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Examination of the GNA12 gene in familial hyperaldosteronism type II (FH-II) patients linked to chromosome 7p22 found no causative mutations in GNA12, providing a negative result for GNA12 as the causal gene for FH-II in the families studied.\",\n      \"method\": \"DNA sequencing of GNA12 coding regions in affected and unaffected members of 7p22-linked FH-II families\",\n      \"journal\": \"Clinical and experimental pharmacology & physiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — negative finding from candidate gene sequencing in small family cohort; informationally relevant as negative result\",\n      \"pmids\": [\"18307725\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GNA12 encodes Gα12, the α-subunit of the G12 family of heterotrimeric G proteins (the gep proto-oncogene), which is activated downstream of GPCRs (including LPA receptors) and signals through multiple effectors: it activates JNK via the scaffold protein JLP, stimulates STAT3 phosphorylation via JAK3/Src (Tyr705) and PDGFRα/PI3K (Ser727), activates CREB via a Ras-ERK-dependent mechanism, promotes YAP activity through the Hippo pathway, upregulates TGFβ1 transcription via Rho/Rac-dependent AP-1 activation, and in HCC drives EMT by suppressing p53 (through AP-1/MDM2) to derepress ZEB1 via miR-200/192/215 clusters; GNA12 transcription itself is positively controlled by c-Jun binding to a minimal 784 bp promoter element.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GNA12 encodes Gα12, the α-subunit of the G12 heterotrimeric G protein (the gep proto-oncogene), which couples GPCR activation — notably LPA receptors — to a transcriptional program driving cell proliferation and neoplastic transformation [#3, #6]. Upon activation, Gα12 engages multiple effector routes: it associates with the scaffold protein JLP through JLP's C-terminal domain to drive JNK activation, an interaction required for Gα12/Gα13-mediated transformation [#2]; it phosphorylates and activates STAT3 at Tyr705 (via JAK3/Src) and Ser727 (via PDGFRα/PI3K), with STAT3 acting as a critical mediator of transformation [#0]; and it stimulates CREB phosphorylation at Ser133 through a cAMP-independent, Ras-ERK-dependent route that supports LPA-driven proliferation [#4]. Through Rho/Rac-dependent activation of AP-1 (c-Jun), Gα12 upregulates TGFβ1 transcription [#1], and it activates the Hippo-pathway coactivator YAP to promote ovarian cancer cell growth [#7]. In hepatocellular carcinoma, activated Gα12 drives epithelial-mesenchymal transition by inducing MDM2 through AP-1/c-Jun, lowering p53 and thereby derepressing ZEB1 via the p53-responsive miR-200/192/215 microRNA clusters [#5]. GNA12 expression is itself positively controlled by c-Jun binding to a minimal 784 bp promoter region [#8]. In vivo, silencing Gα12 (and Gα13) reduces xenograft tumor growth, establishing the G12 family α-subunits as determinants of tumor growth [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that activated Gα12 transforms cells through STAT3, identifying a defined downstream effector for gep oncogene-driven transformation.\",\n      \"evidence\": \"Constitutively active Gα12QL transfection with phospho-STAT3 immunoblotting, dominant-negative STAT3 co-expression, foci and soft-agar assays\",\n      \"pmids\": [\"16247467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism of how Gα12 engages JAK3/Src and PDGFRα not resolved\", \"STAT3 transcriptional targets in this context not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Tested whether GNA12 physically interacts with regulators and contributes to germ cell biology, linking it to RGS22 in the testis.\",\n      \"evidence\": \"Co-immunoprecipitation of GNA12 with RGS22, GFP-fusion tracking, immunofluorescence and testis histology\",\n      \"pmids\": [\"18703424\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single Co-IP for the GNA12 interaction without reciprocal validation\", \"Localization and phenotype data were for GNA13, not GNA12\", \"No functional manipulation of GNA12\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Excluded GNA12 as the causal gene for familial hyperaldosteronism type II in 7p22-linked families, a negative genetic result.\",\n      \"evidence\": \"DNA sequencing of GNA12 coding regions in FH-II family members\",\n      \"pmids\": [\"18307725\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Small cohort; coding-region only\", \"Does not address regulatory or non-coding variants\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined how Gα12/13 reprograms transcription, showing Rho/Rac-AP-1-dependent upregulation of TGFβ1.\",\n      \"evidence\": \"siRNA knockdown, knockout MEFs, activated mutant rescue, promoter-deletion reporter, AP-1 assay, dominant-negative Rho/Rac/Cdc42\",\n      \"pmids\": [\"19151758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effector linking Gα12 to Rho/Rac not specified\", \"Physiological consequence of TGFβ1 induction not tracked in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified JLP as a Gα12-binding scaffold required for JNK activation and transformation, providing a physical effector link.\",\n      \"evidence\": \"Co-IP, competitive inhibition with JLP C-terminal domain peptide, JNK activity assay, foci formation assay\",\n      \"pmids\": [\"21472140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; structural basis of the interaction not resolved\", \"How JLP couples to the JNK module downstream not detailed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that LPA drives ovarian cancer proliferation specifically through Gα12, separating proliferative from migratory signaling.\",\n      \"evidence\": \"shRNA silencing, inhibitory CT12 minigene disrupting LPAR-Gα12, proliferation and migration assays across multiple cell lines\",\n      \"pmids\": [\"21901169\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream proliferative effectors not defined here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed Gα12 mediates LPA-stimulated CREB activation via a cAMP-independent Ras-ERK route supporting proliferation.\",\n      \"evidence\": \"Constitutively active Gα12, siRNA silencing, phospho-CREB (Ser133) immunoblotting, dominant-negative CREB(S133A), proliferation assay\",\n      \"pmids\": [\"24055910\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link between Gα12 and Ras not mechanistically resolved\", \"CREB target genes not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected Gα12 to EMT in HCC through an AP-1/MDM2/p53/miRNA axis derepressing ZEB1, defining a transcriptional EMT mechanism.\",\n      \"evidence\": \"Gα12QL transfection, miRNome and cDNA profiling, miRNA mimics, shRNA knockdown, xenograft tumor model\",\n      \"pmids\": [\"25065598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same axis operates in non-HCC tumors not established\", \"Proximal effector linking Gα12 to AP-1/MDM2 not fully mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established Gα12/13 as the determinant α-subunits for ovarian tumor growth in vivo, distinguishing them from Gαi2/Gαq.\",\n      \"evidence\": \"siRNA silencing of individual Gα subunits, proliferation and invasion assays, xenograft model with survival analysis\",\n      \"pmids\": [\"26413218\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Gα13 effect was stronger than Gα12; relative contributions not dissected mechanistically\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked GNA12 promoter hypomethylation to elevated expression in preeclampsia, implicating epigenetic control of GNA12.\",\n      \"evidence\": \"MassARRAY CpG methylation analysis of placenta and blood DNA with RT-qPCR\",\n      \"pmids\": [\"26767593\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Correlative association without functional manipulation\", \"Causal direction between methylation and expression not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed Gα12/13 selectively activates the Hippo coactivator YAP to drive ovarian cancer growth, adding a transcriptional growth effector.\",\n      \"evidence\": \"Chimeric G protein/DREADD selective pathway activation, YAP assays, shRNA knockdown, YAP inhibitor, growth assay\",\n      \"pmids\": [\"26804165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream Hippo kinase steps engaged by Gα12 not delineated\", \"Single study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified c-Jun as a specific transcriptional regulator of GNA12, revealing a feedforward loop with AP-1-dependent Gα12 signaling.\",\n      \"evidence\": \"Promoter cloning, luciferase deletion analysis, ChIP, c-Jun siRNA, RT-qPCR and immunoblotting in PC3 cells\",\n      \"pmids\": [\"28394299\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Roles of the co-identified C/EBP and CREB1 sites not functionally tested\", \"Single cell-type/single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Tested post-transcriptional regulation of GNA12, showing a plant-derived miRNA can lower GNA12 and modulate downstream mTOR signaling.\",\n      \"evidence\": \"Bioinformatic prediction and synthetic miR171vr transfection in HEK293 with RT-qPCR/immunoblot\",\n      \"pmids\": [\"33386590\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No 3'UTR reporter or rescue to confirm direct targeting\", \"Physiological relevance of plant miRNA targeting unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse Gα12 effector branches (JLP-JNK, STAT3, CREB, Rho/Rac-AP-1, YAP, p53-miRNA) are integrated and selected in a given cell context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model of effector selection downstream of Gα12\", \"Structural/biochemical basis for differential effector engagement undefined\", \"Limited in vivo validation outside xenograft models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 4, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5, 7]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 4, 7]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 5, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"JLP\", \"RGS22\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}